No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Nov 27, 2024
On 27 November 2024, BeiGene announced that the European Commission approved Tevimbra® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ)...
Nov 27, 2024
On 27 November 2024, Novo Nordisk Canada announced Canadian approval of Wegovy® (semaglutide) for the reduction of risk of non-fatal myocardial infarction in adults with established cardiovascular disease. Wegovy® was approved in Canada for the treatment of...
Nov 26, 2024
On 26 November 2024, CSPC Pharmaceutical Group Limited (CSPC) announced that its biologic license application for ustekinumab (biosimilar to Johnson & Johnson’s Stelara®) was accepted by the People’s Republic of China's National Medical Products Administration...
Nov 26, 2024
On 26 November 2024, Celltrion’s Omlyclo®, biosimilar to Genentech's and Novartis' Xolair® (omalizumab) was approved in Australia. Omlyclo® is the first omalizumab biosimilar approved in Australia. Omylclo® was approved in Australia for two presentations: 75 mg/0.5...
Nov 26, 2024
On 26 November 2024, The Economic Times reported that AstraZeneca has received approval from India's Central Drugs Standard Control Organisation (CSDCO) to market Lynparza® (olaparib) in India. The CDSCO granted approval for the use of Lynparza® in combination with...
Nov 25, 2024
On 25 November 2024, GlaxoSmithKline (GSK) announced that the FDA has accepted its BLA for Blenrep® (belantamab mafodotin) in combination with BorDex (bortezomib plus dexamethasone) or PomDex (pomalidomide plus dexamethasone) for the treatment of patients with...
Nov 22, 2024
On 22 November 2024, Chugai (a Roche subsidiary) and Zenyaku Kogyo announced that their co-marketed Rituxan® (rituximab) has been approved by the Japanese Ministry of Health, Labour and Welfare for chronic idiopathic thrombocytopenic purpura (ITP) in children (IV...
Nov 22, 2024
On 22 November 2024, Johnson & Johnson submitted a supplemental Biologics License Application to the FDA seeking approval of a subcutaneous (SC) induction regimen of Tremfya® (guselkumab) for the treatment of adults with moderately to severely active ulcerative...
Nov 22, 2024
On 22 November 2024, Celltrion announced that the Korean Ministry of Food and Drug Safety has approved its Stoboclo™ (CT-P41, denosumab) and Osenvelt™ (CT-P41, denosumab), biosimilars to Amgen’s Prolia® and Xgeva®, respectively. Stoboclo™ and Osenvelt™ are the first...
Nov 21, 2024
On 21 November 2024, Replimune announced that it has submitted a biologics license application (BLA) to the FDA for RP1 (vusolimogene oderparepvec, a genetically modified oncolytic strain of HSV-1 virus) in combination with Opdivo® (nivolumab) for the treatment of...
Nov 20, 2024
We reported on 26 August 2024 that JAMP had filed an application in the Canadian Competition Tribunal seeking leave to bring an action under the Competition Act regarding Stelara®
Nov 20, 2024
On 20 November 2024, Jazz Pharmaceuticals announced that the US FDA has granted accelerated approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.